IL2 and neoplasm: Even with a reduced IL-2 dose and frequency, i.t. administration of nanobody–IL-2 fusions to B16F10 tumors markedly reduced tumor growth and led to a more pronounced benefit from enhanced affinity for EIIIB (Fig. 5B).